Results 231 to 240 of about 118,382 (307)

Memantine treatment improves opioid-induced hyperalgesia symptoms: randomize clinical trial. [PDF]

Sci Rep
Anjomshoaa A, Zolghadriha A, Haj-Seyed-Taghia NS, Saed O, Faghihzadeh E.   +4 more
europepmc   +1 more source

Development of a novel risk score reflecting the relative harm potential of synthetic cannabinoids based on prevalence estimates, well‐documented intoxication cases and basic pharmacological data

Addiction, EarlyView.
Abstract Background and aims While the health hazards of synthetic cannabinoid receptor agonists (SCRAs) are often approximated using in vitro pharmacological parameters as surrogate, this approach fails to consider pharmacokinetic and pharmacodynamic complexity.
Michaela J. Sommer, Katharina Elisabeth Grafinger, Maren Hermanns‐Clausen, Volker Auwärter   +3 more
wiley   +1 more source

The Orexin System in Addiction: Neuromodulatory Interactions and Therapeutic Potential. [PDF]

Brain Sci
Capó T, Lillo J, Rebassa JB, Badia P, Raïch I, Cubeles-Juberias E, Reyes-Resina I, Navarro G.   +7 more
europepmc   +1 more source

Outdated tools, underestimated harm: Modernizing cannabis surveillance in a post‐legalization era

Addiction, EarlyView.
Abstract Background Canada's 2018 legalization of non‐medical cannabis was positioned as a public health initiative, intended to shift cannabis use from criminalization to regulation. Since then, cannabis access and consumption have grown significantly but the systems used to monitor cannabis‐related harms have not kept pace.
Anees Bahji
wiley   +1 more source

Genetic and Epigenetic Approaches to Opioid Use Disorder. [PDF]

Expert Rev Mol Med
Ranadeva ND, Wijekumar PJ, Fernando CA, Jayamaha AR, Noordeen N, Chackrewarthy S, Fernando N.   +6 more
europepmc   +1 more source

A cost–benefit analysis of the implementation and scale‐up of harm reduction interventions in the Australian Capital Territory

Addiction, EarlyView.
Abstract Background and aims Harm reduction interventions aim to reduce negative consequences of drug use. We aimed to estimate the cost, health impact and economic benefits of current, expanded and new harm reduction interventions for people who use drugs in the Australian Capital Territory.
Anna L. Bowring, Tom Tidhar, Anna Olsen, Christopher Bailie, Kelvin Burke, Rowan Martin‐Hughes, Helen Keane, Paul Dietze, Nick Scott   +8 more
wiley   +1 more source

The role of nucleus accumbens dopamine signaling in the development of morphine tolerance in neuropathic pain. [PDF]

Korean J Pain
Cui S, Kim WM, Jang EA, Lee YJ, Kang DH, Lee HG, Choi JI.   +6 more
europepmc   +1 more source

Detecting cannabis use reduction through biochemical verification of urinary cannabinoids: An aggregated analysis of cannabis use disorder treatment trials examining average reductions and individual cut‐points

Addiction, EarlyView.
Abstract Background and aims Currently, there is no data‐driven cannabis reduction metric using biochemical verification, which represents a significant gap in cannabis harm reduction research, treatment and policy. Using aggregated data from 7 cannabis use disorder treatment trials, the aims of this analysis were to 1) determine if decreases in self ...
Erin A. McClure, Brian Neelon, Rachel L. Tomko, Ashley Dowd, Kevin M. Gray, Aimee L. McRae‐Clark, Nathaniel Baker   +6 more
wiley   +1 more source

Cannabidiol reduces oxycodone self-administration while preserving its analgesic efficacy in a rat model of neuropathic pain. [PDF]

Sci Rep
Bruijnzeel AW, Behnood-Rod A, Chellian R, Malphurs W, Caudle RM, Febo M, Setlow B, Murphy NP, Neubert JK.   +8 more
europepmc   +1 more source

Varenicline for cannabis use disorder: A randomized controlled trial

Addiction, EarlyView.
Abstract Background and aims Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment‐seeking individuals with CUD ...
Aimee L. McRae‐Clark, Kevin M. Gray, Nathaniel L. Baker, Brian J. Sherman, Bryan Tolliver, Jessica Burt, Alonzo Steplight, Elizabeth Chapman, Amanda Wagner   +8 more
wiley   +1 more source